prevalence and penetrance of BRCA mutations Familial susceptibility to breast cancer accounts for 25% of all breast cancer cases. In familial breast cancer, mutations in the BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account for 5-10% of breast and ovarian cancer cases overall. The prevalence of BRCA1 or BRCA2 mutations varies considerably between ethnic groups and geographical areas. Populationspecific mutations have been described in Iceland, the Netherlands, Sweden, Norway, Germany, France, Spain, countries of central and eastern Europe and among Ashkenazi Jews. The prevalence of BRCA mutation carriers in the general population is estimated at between 1/800 and 1/1000. BRCA1 and BRCA2 mutation frequencies in breast and ovarian cancer patients unselected for family history or age at onset are generally low (<1-7% for BRCA1 and 1-3% for BRCA2). Higher prevalence is associated with a family history of breast or ovarian cancer, young age at onset, male breast cancer or multiple tumors (bilateral breast cancer or breast and ovarian cancer in the same patient).
referral for BRCA testing Genetic testing criteria may differ between countries based on mutation prevalence. Widely accepted criteria for referral include: three or more breast and/or ovarian cancer cases, at least one aged <50 years; two breast cancer cases aged <40 years; male breast cancer and early onset female breast cancer; and breast and ovarian cancer in the same patient [IV, C]. In some countries, the criterion for testing is that there should be at least a 10-20% probability of finding a mutation. In all cases, genetic testing should be performed after genetic counseling and informed consent. Short-term hormonal replacement therapy after bilateral salpingo-oophorectomy seems not to decrease the overall benefit of this strategy for breast cancer risk reduction [III, B] .
mutation detection

breast cancer treatment
Decisions about surgical treatment of breast cancer in BRCA mutation carriers should be based on the same parameters as sporadic cancer, while considering the higher risk of contralateral breast cancer [III, B] .
Standard prognostic features should be used to decide adjuvant treatment in BRCA mutation carriers with breast cancer. Ongoing clinical trials in the metastatic setting are testing the sensitivity to platinum-based chemotherapy of BRCA tumors and the specific DNA-repair deficiency with the use of PARP inhibitors. literature
